Diagnostics and Drug Delivery Devices

Techno Medica Co., Ltd.

6678

3671

4570

<p>ImmunoForge Co., Ltd. will participate in Bio-Europe Spring 2026 in Lisbon to engage in strategic meetings with global pharmaceutical companies and investors. The company aims to discuss its proprietary BBB Shuttle platform, LMT15, and out-licensing of its Phase 2 drugs, PF1801 and PF1804. ImmunoForge is focused on promoting collaboration and technology transfer, particularly regarding its long-acting ELP platform and CNS-targeted drug development. The company is currently accepting meeting requests for the event.</p>

Techno Medica Co., Ltd.(6678.JP)

04:58 ETImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026